Prenetics’ IM8 Launches Daily Ultimate Longevity, First Supplement to Target All 12 Hallmarks of Aging
Rhea-AI Summary
Prenetics (NASDAQ: PRE) announced on October 8, 2025 the launch of Daily Ultimate Longevity under its IM8 brand. The powder formulation is described as the first supplement to target all 12 hallmarks of aging using a five-complex system with specified clinical ingredient doses (e.g., 3,000 mg glycine, 300 mg NMN, 3 mg spermidine).
IM8 reported rapid scaling from approximately $600k monthly at launch to $6.6M monthly revenue in September 2025 and cites a 2,457% CAGR, targeting $100M ARR within its first year. Product pricing is $149 one-time or $119/month subscription. Prenetics reports >$90M liquid assets (≈$60M cash and 255.4 BTC ≈$31.6M) and says it is debt-free with a path to profitability in early 2026.
Positive
- Monthly revenue scaled to $6.6M in September 2025
- Claimed compound annual growth rate of 2,457%
- Company targets $100M annual recurring revenue within first year
- Reported >$90M liquid assets including ~$60M cash
- Debt-free with stated path to profitability in early 2026
- Product lists specific clinical doses (e.g., 300 mg NMN, 3 mg spermidine)
Negative
- NSF certification for the product is listed as pending
- Targeting $100M ARR is a forward projection, not yet achieved
- Exclusive direct sales at IM8health.com may limit distribution reach
News Market Reaction 2 Alerts
On the day this news was published, PRE declined 5.33%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. The stock closed at $14.02 on that trading session. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $183M at that time.
Data tracked by StockTitan Argus on the day of publication.
Launch Follows IM8’s Record Growth to
IM8 Accelerates Toward
CHARLOTTE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, today announced the launch of Daily Ultimate Longevity from its rapidly scaling IM8 Health brand co-founded by David Beckham. Daily Ultimate Longevity is the first supplement scientifically formulated to comprehensively target all 12 hallmarks of aging, reinforcing IM8's position as one of the fastest-growing supplement brand in industry history. Since its full December 2024 launch, IM8 has achieved an extraordinary compound annual growth rate of 2,

Unprecedented Market Performance Drives Innovation
Daily Ultimate Longevity represents the first supplement scientifically formulated to support all 12 hallmarks of aging as defined by landmark research published in the journal Cell (López-Otín et al., 2023). Developed in collaboration with doctors and scientists from Mayo Clinic and the former Chief Scientist of NASA, the formulation features IM8's proprietary 5-Complex System, delivering therapeutic doses of premium, clinically-validated ingredients in an advanced powder format that provides 1,
Danny Yeung, Chief Executive Officer and Co-Founder of Prenetics / IM8, said, “Today's launch of the new advanced Daily Ultimate Longevity represents the culmination of our relentless pursuit to create the world's most advanced health optimization products.” Danny further added, “As we approach our unprecedented
David Beckham, Co-Founder of IM8, said, “At IM8, our vision has always been to create the best quality products that really make a difference. I’m proud to see how the company's reputation has positively grown over the past year and excited that today we're launching Daily Ultimate Longevity to further expand our offering. I take it every morning with the Daily Ultimate Essentials drink – together, they taste great and give me the confidence that I'm supporting my health now, and for the future.”
Revolutionary 5-Complex System Addresses Complete Aging Spectrum
Daily Ultimate Longevity’s five synergistic complexes are clinically dosed to target key aging pathways including cellular senescence, mitochondrial dysfunction, and DNA repair—the same biological processes identified in the landmark Cell journal research defining the 12 Hallmarks of Aging:
- Cellular Foundation Builder – Provides essential building blocks for cellular repair with 3,000 mg of glycine and 2,000 mg of taurine, doses shown in human studies to support sleep quality, metabolic health, and healthy lifespan.
- Cellular Protection Activator (Senolytics) – Combines 250 mg trans-resveratrol, 250 mg quercetin, and 100 mg fisetin, three clinically studied compounds shown to help clear senescent cells and protect against oxidative damage.
- NMN NAD⁺ Energy Booster – Features 300 mg pharmaceutical-grade nicotinamide mononucleotide (NMN) and 10 mg PQQ, the same combination and dosage range proven in multiple clinical trials to elevate NAD⁺ levels, enhance mitochondrial function, and promote cellular energy.
- Metabolic AMPK/SIRT1 Activator – Includes 100 mg dihydroberberine, a next-generation form offering five times the bioavailability of standard berberine, along with 6 mg AstaPure® astaxanthin for metabolic and antioxidant support.
- Cellular Renewal Activator (Autophagy) – Delivers 3 mg spermidine, the clinically recommended daily dose for individuals, promoting natural autophagy and cellular renewal for healthy aging.
Together, these five complexes form the first daily nutrition formula designed to comprehensively target all 12 Hallmarks of Aging, supported by human clinical research and tested for safety and purity.
Category-Defining Innovation in Rapidly Growing Market
The global longevity market is projected to reach
“We created the most advanced longevity supplement on the market, featuring key ingredients like high-dose glycine and taurine, powerful senolytic compounds including quercetin and fisetin, NAD+ boosters NMN and PQQ, plus metabolic enhancers like dihydroberberine,” said Dr. Darshan Shah, Board Certified Surgeon & Physician and IM8 Scientific Advisory Board member. “The five synergistic complexes of the new advanced Daily Ultimate Longevity target cellular senescence, one of the primary hallmarks of aging, while promoting comprehensive cellular energy support and DNA repair.”
The powder format enables seamless integration with IM8's flagship Daily Ultimate Essentials, creating what the company calls the “Enhanced Beckham Stack” – a comprehensive daily health optimization routine that addresses both foundational nutrition and advanced longevity support in a single, convenient drink.
Premium Positioning with Proven Results
Daily Ultimate Longevity maintains IM8's commitment to premium quality with NSF certification (pending), vegan, non-GMO, gluten-free formulation free from all major allergens. Available exclusively at IM8health.com, it is priced at
Strong Financial Foundation Supports Continued Innovation
Prenetics' strong financial position, with more than
For Media and Product Photos: Link
About Prenetics
Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer health. Our consumer initiative is led by IM8, one of the World’s fastest growing supplement brands, Europa, one of the largest sports distribution companies in the USA, and CircleDNA, a leading direct-to-consumer DNA test. As the first consumer healthcare company to establish a Bitcoin treasury with its initial
About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as co-founding partner and an elite team of scientists spanning medical professionals, academia, and space science. Combining cutting-edge science with nature's most potent ingredients, IM8 delivers a holistic, science-backed approach to health optimization. IM8's flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors, or sweeteners. IM8 is a subsidiary of Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company dedicated to advancing consumer health.
Investor Relations Contact:
investors@prenetics.com
PRE@mzgroup.us
Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com
Media Contact Jack Taylor PR im8@jacktaylorpr.com
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar statements. Prenetics may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (“SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Prenetics’ beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not to the following: the Company’s ability to execute its strategies, manage its growth, and achieve and maintain profitability; the Company’s ability to develop and commercialize its products and services; the Company’s ability to maintain and enhance its brand; the Company’s ability to compete effectively; the Company’s ability to continue to develop and maintain relationships with its partners and customers; the Company’s ability to protect its intellectual property; the Company’s ability to comply with applicable laws and regulations; and the Company’s ability to obtain additional financing. Further information regarding these and other risks is included in Prenetics’ filings with the SEC. All information provided in this press release is as of the date of this press release, and Prenetics does not undertake any duty to update such information, except as required under applicable law.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9c511650-330b-413c-824e-f0c1de5c9ad5